Get the Stockscreener App
58.57
6.30%
3.47
After Hours:
58.00
-0.57
-0.97%
Guardant Health Inc stock is traded at $58.57, with a volume of 3.05M.
It is up +6.30% in the last 24 hours and up +16.56% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$55.10
Open:
$55.395
24h Volume:
3.05M
Relative Volume:
1.33
Market Cap:
$7.30B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-13.81
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+31.35%
1M Performance:
+16.56%
6M Performance:
+24.67%
1Y Performance:
+96.94%
1-Day Range:
$55.14
$58.62
1-Week Range:
$48.25
$58.62
52-Week Range:
$20.14
$58.62
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
58.57 | 6.87B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know - TradingView
Astrana Health, agilon health, Guardant Health, AdaptHealth, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent
Guardant Health at Canaccord Conference: Strategic Growth Unveiled By Investing.com - Investing.com Canada
GH Q2 Deep Dive: Strong Volume Growth and Product Expansion Amid Profitability Challenges - Yahoo Finance
The 5 Most Interesting Analyst Questions From Guardant Health’s Q2 Earnings Call - Yahoo Finance
Is Guardant Health Inc. impacted by rising ratesReal Return Trading Plans - newsyoung.net
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - uk.finance.yahoo.com
Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening - MedCity News
Weekly Market Update: Stocks Rise as Basic Materials and Tech Gain - Morningstar
Guardant Health Surges 7.62% on $250M Volume Despite 396th Market Activity Rank - AInvest
Guardant Health Surges 13% on 197% Volume Spike Ranks 269th in Market Activity - AInvest
Guardant Health stock hits 52-week high at 53.49 USD By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 53.49 USD - Investing.com
Guardant Health Soars 17.2% on Q2 Earnings Beat - AInvest
Exact Sciences acquires rights to rival Freenome’s blood-based colon cancer test - statnews.com
Multi-Cancer Early Detection Market Set to Revolutionize Cancer Diagnosis by 2034 | Driven by Liquid Biopsy Innovations and AI Integration - PharmiWeb.com
The Oncology Institute, Inc. shares rise 3.94% intraday after American Cancer Society and Guardant Health partnership. - AInvest
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity - Business Wire
Is It Too Late to Sell Guardant Health Inc.Intraday Trend Analysis for Fast Gains Released - beatles.ru
Why is Guardant Health Inc. stock attracting strong analyst attentionRobust financial gains - Jammu Links News
What drives Guardant Health Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What is the risk reward ratio of investing in Guardant Health Inc. stockExceptional market positioning - Jammu Links News
Should I hold or sell Guardant Health Inc. stock in 2025Maximize portfolio value with expert tips - Jammu Links News
What catalysts could drive Guardant Health Inc. stock higher in 2025Exceptional trading results - Jammu Links News
How volatile is Guardant Health Inc. stock compared to the marketHarness the power of proven investment plans - Jammu Links News
What institutional investors are buying Guardant Health Inc. stockSignificant capital appreciation - Jammu Links News
Does Guardant Health Inc. stock perform well during market downturnsUnlock powerful portfolio management tools - Jammu Links News
What is Guardant Health Inc. company’s growth strategyMarket-leading growth rates - Jammu Links News
Is Guardant Health Inc. a growth stock or a value stockRapid growth trajectories - Jammu Links News
What are Guardant Health Inc. company’s key revenue driversStrong return on assets - Jammu Links News
Is Guardant Health Inc. stock overvalued or undervaluedAchieve breakthrough performance with smart picks - Jammu Links News
How many analysts rate Guardant Health Inc. as a “Buy”Unlock powerful portfolio management tools - Jammu Links News
Guardant Health, Inc. (NASDAQ:GH) Q2 2025 Earnings Call Transcript - Insider Monkey
Guardant Health Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Guardant Health Reports Strong Q2 2025 Growth - The Globe and Mail
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Benzinga
Guardant Health's Q2 2025: Unpacking Contradictions in Volume Growth, Medicaid Impact, and Market Strategy - AInvest
Guardant Health’s Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay Concerns - TipRanks
Scotiabank raises Guardant Health stock price target to $60 on strong results - Investing.com Australia
Top Analysts Recommend 3 Strong Buy Stocks: Apellis Pharmaceuticals, Guardant Health, and Silvaco Group - AInvest
Guardant Health Beat Wall Street Expectations And Raised Its Outlook - Finimize
Guardant Health 2025 Q2 Earnings Mixed Results as Net Loss Narrows - AInvest
Guardant Health (GH) Q2 Revenue Up 31% - The Motley Fool
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
Guardant Health: Q2 Earnings Snapshot - CTPost
Guardant Health (GH): Navigating Growth, Margins, and Valuation in a Competitive Healthcare Innovation Landscape - AInvest
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise By Investing.com - Investing.com South Africa
Earnings call transcript: Guardant Health beats Q2 2025 forecasts, shares rise - Investing.com Canada
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.96%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):